Abattis Bioceuticals EBIT

Abattis Bioceuticals (ATTBF) currently reports a EBIT of $-3.9M as of September 2019. That compares with $-17M in the prior-year period — up 77.5% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore Abattis Bioceuticals's EBIT history and peer comparisons.

Abattis Bioceuticals's EBIT increased from $-17M to $-3.9M — a 77.5% year-over-year increase (period ending September 2019). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Abattis Bioceuticals's EBIT of $-3.9M is lower than the Healthcare sector average of $110B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Abattis Bioceuticals reported $-3.9M in EBIT as of September 2019. That compares with $-17M in the prior-year period — up 77.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-3.9M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for Abattis Bioceuticals, and consider following ATTBF for alerts when major investors trade the stock.